Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood test vs. scalpel: could liquid biopsy replace tissue biopsies for cancer monitoring?

NCT ID NCT05245136

Knowledge-focused Sponsor: University Hospital Augsburg Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 30, 2026 · Last updated Jul 31, 2026 · Updated 1 time

Summary

This large observational study is testing whether a blood-based 'liquid biopsy' can detect tumor mutations and track disease progression in people with metastatic or advanced solid tumors who are receiving palliative care. Researchers will compare results from liquid biopsies with standard tissue biopsies to see how well they match. The goal is to understand if liquid biopsy can serve as a reliable, less invasive tool for diagnosis and monitoring.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could show that a simple blood test (liquid biopsy) can reliably detect cancer mutations and monitor disease progression, potentially reducing the need for invasive tissue biopsies.
What could go wrong
This is an observational study, not a treatment trial, so it won't directly improve outcomes. Liquid biopsy may not be accurate enough to replace tissue biopsy in all cases.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 3,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2021

Expected to finish

Mar 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Study population consists of patients with diagnosis of metastatic cancer at the University Hospital Augsburg.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Written informed consent * Age ≥ 18 years * Histopathologically confirmed metastatic or locally advanced cancer * No curative treatment options, except for germ cell tumors * Written Agreement to be followed up at Augsburg University Medical Center * Signed written informed consent for the Biobank Augsburg (Biobank-A) * Willing to undergo treatment according to standard of care * Availability or anticipated availability of tumor tissue at time point of inclusion * Anticipated life expectancy of at least 3 months at time point of trial inclusion Exclusion Criteria: * Psychological condition that would preclude informed consent * Additional tumor treatment between acquisition of tumor tissue and trial inclusion

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Characteristics disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

disease characteristic metastatic malignant neoplasm neoplasm Neoplasm Metastasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Characteristics disease Metastatic cancer Solid tumor

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University Hospital Augsburg

    RECRUITING

    Augsburg, Bavaria, 86156, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.